Actrapid Pharmacokinetic Profile
Actrapid is regular human insulin with an onset of action around 30 minutes, peak effect at 2-3 hours, and duration of 6-8 hours after subcutaneous injection.
Absorption Characteristics
Actrapid (regular human insulin) exhibits slower and more delayed absorption kinetics compared to rapid-acting insulin analogs 1. The absorption follows a multiphasic pattern:
- Initial phase (0-2 hours): Fractional disappearance rate of approximately 20.7%/h
- Second phase (2.5-5 hours): Rate increases to ~45.6%/h
- Third phase (>5 hours): Further acceleration to ~70.6%/h 1
This triphasic absorption pattern occurs because Actrapid exists as hexameric insulin in pharmaceutical formulation and must progressively dissociate into dimers and monomers before absorption can occur 1. The molecular aggregation state is the primary determinant of absorption rate.
Clinical Pharmacology
When administered subcutaneously:
- Onset: Begins within 30 minutes of injection
- Peak plasma levels: Achieved at approximately 2-3 hours post-injection 2, 3
- Duration of action: 6-8 hours
- Timing: Should be injected 30 minutes before meals to align peak insulin action with postprandial glucose rise 4
The absorption of Actrapid is significantly slower than rapid-acting analogs (lispro, aspart), which reach peak levels at 30 minutes and have fractional disappearance rates exceeding 67%/h 1, 5.
Clinical Context
While modern guidelines favor rapid-acting insulin analogs over regular human insulin for mealtime coverage due to superior postprandial glucose control and reduced hypoglycemia risk 6, Actrapid remains a viable option when:
- Cost or access to analogs is prohibitive
- Patients require a defined insulin treatment plan to prevent diabetic ketoacidosis 6
The DCCT demonstrated that intensive therapy using regular human insulin (like Actrapid) achieved 50% reductions in microvascular complications, though with higher rates of severe hypoglycemia compared to modern analog-based regimens 6.
Important Caveats
- Intra- and inter-individual variability in absorption is directly proportional to insulin duration of action - Actrapid shows more variability than rapid-acting analogs 4
- The 30-minute pre-meal injection requirement makes Actrapid less convenient and physiologic than analogs that can be injected immediately before eating 5
- Lipohypertrophy at injection sites significantly distorts absorption - proper site rotation is essential 7
Human insulin (Actrapid) demonstrated accelerated absorption and stronger hypoglycemic effect compared to porcine insulin preparations in early comparative studies 2, though this distinction is now primarily of historical interest.